Drug-drug interactions (DDIs) with serious adverse consequences for patients at intensive care unit (ICU) occur with the prevalence of 5.3%. The aim of our study was to reveal the risk factors for potential DDIs among the ICU patients.
I N T R O D U C T I O N
Drug-drug interactions (DDIs) with serious adverse consequences for patients at intensive care unit (ICU) occur with high prevalence of 5.3% and are responsible for almost 15 .5% of all adverse drug reactions in that patient population (1) . In principle, DDIs are all preventable if potential for their occurrence is noticed on time (2) . There are numerous softwares providing for rapid, bed-side discovery of clinically relevant potential DDIs, which were already validated in practice, and demonstrated significant sensitivity and specificity. However, such tools differ among themselves in severity classification of DDIs and recommendations, and their use should be considered as a screening procedure only (3) .
As with any screening tool, effectiveness of DDI checkers is much higher if used in subpopulations with high risk of the target problem. Risk factors for DDIs in patients at ICU were studied in several settings, and the following were repeatedly reported: the length of stay and number of drugs or therapeutic groups prescribed (3) (4) (5) (6) . However, a few other risk factors may be of importance, especially prescription of certain drug groups which are prone to DDIs, like anticonvulsants or anticoagulans (3), but their true significance remain to be elucidated. The aim of our study was to test the significance of previously identified risk factors for potential DDIs, as well as to search for other not yet investigated risk factors which could help with more precise definition of subpopulation of the ICU patients with high risk for DDIs.
M E T H O D S
We conducted retrospective cohort analysis of patients treated at the Intensive Care Unit of the Clinical Center (CC), a public tertiary care hospital in Podgorica, Montenegro. The cohort consisted of all consecutive patients who were admitted to the 34-beds ICU between June 1, 2017 and September 30, 2018. The Ethics Committee of Clinical Center Podgorica had approved the study prior to its onset (No 03/01-1055/1 on 13.03.2017.).
The data used for the study were collected from the patient's files. The data about the patients' drug treatment, sociodemographic characteristics, and current conditions which could be potential risk factors for the occurrence of drug-drug interactions were entered in the study database. The drugs were classified according to the Anatomical Therapeutic Chemical Classification codes (ATC) (7) . The following variables were followed in this study: socio-demographic data of the patients (age, gender), clinical history data (main diagnosis, length of stay in the hospital, mechanical ventilation, transfer from other departments to the ICU, state of consciousness, previous surgery), comorbidities (especially the presence of dementia or delirium, renal failure, liver failure, diabetes mellitus, chronic obstructive pulmonary disease, bronchial asthma, heart failure, hypertension), Charlson Comorbidity Index (8) , and hospital medication details (total number of prescribed drugs, number of different pharmacological/therapeutic subgroups [2 nd level of ATC classification] prescribed, prescription of antiplatelet drugs, anticoagulants, antiepileptic drugs, antidepressants, antiarrhythmic drugs (other drug groups could not be used as variables, because either such drugs were prescribed to almost every patient, e.g. analgesics or antibiotics, or just a few patients (or nobody) received particular drug group), drug-related allergy, number of physicians who prescribed therapy to a particular patient, and interaction checker data (number and description of the DDI). Prescribed drugs were administered according to the recommendations of Summaries of product characteristics (SPCs) issued by Montenegrin Drug Agency, starting with first doses for each day at 8 a.m.
The potential DDI in our study was defined as a possible interaction between two drugs, which might cause an alteration of the therapeutic effect and/or the toxicity of one or both of the drugs involved. The presence and classification of drug-drug interactions was determined by parallel use of two relevant interaction checker databases which operate on the principle of Internet and Smartphone applications: Medscape (9) and Epocrates (10) . Medscape had categories of the severity of DDIs as Contraindicated, Serious -Use alternative, Monitor closely and Minor, and Epocrates as Contraindicated, Avoid/ use alternative, Monitor/modify therapy and Caution advised. We clustered Contraindicated and Serious -use alternative DDIs according to Medscape as "potential DDIs that require change of drug therapy", as well as Contraindicated and Avoid/ use alternative according to Epocrates. The drug-enteral nutrition interactions were not observed in the study.
Statistics
The study data were in the first place tabulated and analyzed by descriptive statistics. Mean and median were used as a measure of central tendency and standard deviation and range as measures of dispersion for continuous variables. Values of categorical variables were presented as numbers or percentages. Multiple li-near regression analysis was used to investigate the influence of potential risk factors on number of drug-drug interactions per patient. Statistical validity of the regression model was tested by analysis of variance (F value) and percentage of explained variability of the outcome (R 2 ). The influence of potential risk factors on the number of DDIs per patient was assessed by their B coefficients within the regression equation, including confidence intervals (CIs). All calculations were performed by the Statistical Program for Social Sciences (SPSS version 18).
R E S U L T S
The study sample included 99 patients (32 females and 67 males) hospitalized at Intensive Care Unit (ICU) of Clinical Center in Podgorica, Montenegro. An average age of the patients was 56.0 ± 18.2 years. Ninetyfour percent of patients had at least one potential DDI, while 20% of patients had at least one potential DDI which required a change of therapy. Detailed characteristics of the study patients are shown in Table 1 . When the number of potential DDIs per patient according to the Medscape interaction checker was taken as the outcome variable, multiple linear regression model (R 2 = 0.773, F = 33.012, p = 0.000) included the following independent and confounding variables: the number of drugs prescribed per patient, number of therapeutic groups (according to the ATC classification) prescribed per patient, prescription of double antiplatelet therapy, drug allergy, smoking and prescription of antiar-rhythmics. Unstandardized B coefficients, their 95% confidence intervals and p-values are shown in Table 2 only for variables with significant influence on the outcome variable, for the purpose of clarity.
Multiple linear regression model with the total number of potential DDIs per patient according to the Epocrates interaction checker was slightly less explanatory (R 2 = 0.645, F = 36.872, p = 0.000), and included the following predictors: the number of drugs prescribed per patient, prescription of double antiplatelet therapy and diagnosis of delirium or dementia. However, only the number of drugs prescribed per patient and diagnosis of delirium or dementia were significant predictors, as shown in Table 2 .
When the number of potential DDIs per patient that require a change of drug therapy according to the Medscape was taken as the outcome variable, a multiple linear regression model (R 2 = 0.402, F = 7.918, p = 0.000) included the following independent and confounding variables: the number of therapeutic groups (according to the ATC classification) prescribed per patient, prescription of double antiplatelet therapy, prescription of antiarrhythmics, prescription of anticoagulant therapy and Charlson Comorbidity Index. Unstandardized B coefficients, their 95% confidence intervals and p-values are shown in Table 2 only for variables with significant influence on the outcome variable, again for the purpose of clarity.
Finally, the multiple linear regression model with the number of potential DDIs per patient that require a change of drug therapy according to the Epocrates was more explanatory than that with Medscape and therapychanging DDIs (R 2 = 0.662, F = 18.892, p = 0.000), and included the following predictors: sex of a patient, number of drugs prescribed per patient, number of therapeutic groups (according to the ATC classification) prescribed per patient, prescription of double antiplatelet therapy, drug allergy and prescription of an anticonvulsant. However, only the sex of a patient, number of drugs prescribed per patient, number of therapeutic groups (according to the ATC classification) prescribed per patient, prescription of double antiplatelet therapy and drug allergy were significant predictors, as shown in Table 2 . The most frequent potential DDIs found in our study that require a change of drug therapy according to Medscape and Epocrates interaction checkers are shown in Table 3 . 
D I S C U S S I O N
Our study confirmed the findings of others that the larger number of drugs (or therapeutic groups) prescribed per patient increases the number of potential DDIs in ICU patients, including those which require a change of therapy. However, we also found that the patients who were prescribed antiarrhythmics, anticoagulants or two antiplatelet drugs experienced more DDIs than patients without these therapeutic groups. On the other hand, delirium or dementia and drug allergy were protective factors, which largely decreased the chances of and the number of DDIs. Finally, the male sex increased the chances of DDIs in ICU patients.
While the number of prescribed drugs or drug groups is linked to chances of DDIs for purely mathematical (statistical) reasons (11) , an increased number of DDIs after prescription of antiarrhythmics, anticoagulants or antiplatelet drugs could be explained by high potential of these drugs to interact both pharmacokinetically and pharmacodynamically with numerous drugs from other groups. Indeed, studies of ICU patients showed that agents acting on the cardiovascular system, aggregation and coagulation are the most frequently engaged in DDIs (12, 13) because coagulation and platelet aggregation are complex processes with multiple regulatory points (where many drugs may interfere) and heart rhythm is based on coordinated functioning of ion channels, which are target of action not only of antiarrhythmics, but of anticonvulsants, anesthetics, psychotropic drugs, and others (14) . Although only 10% of our patients received double antiplatelet therapy and only 13% antiarrhythmic drugs, DDIs from these groups were among the top five (Table 3) .
Delirium and dementia are drug-induced in about 10% of cases (15) , but, paradoxically, when observed in a patient, they may have protective effect against DDIs, as observed in our study. Deleterious effects of delirium in ICU patients were recognized, and current guidelines for treatment of such patients require among other careful analysis adjustment of drug therapy as well, which decreases the chances of DDIs (16) . Routine checking of prescribed drug therapy for DDIs in ICU patients with the signs of delirium or dementia is increasingly performed in various healthcare settings (17) .
Protective effect of drug allergy status of an ICU patient against DDIs could be explained by increased attention of prescribers to all aspects of drug therapy when prescribing to such patients. Prescribers not only avoid all drugs and drug groups which may cross-react with the drug a patient is allergic to, but also check for potential DDIs, which is not a routine procedure otherwise (18) .
Although in our study male sex turned to be a weak risk factor for potential DDIs in ICU patients, other studies gave conflicting results, either showing no influence of gender, or favoring either female or male sex interchangeably (19) (3) (20) . Further studies are necessary to clarify the influence of gender to DDIs in ICU patients.
The main limitations of our study were its unicenterdness, which allows for certain degree of bias introduced by local policies and practices, and a relatively small study sample, dictated by admission rate to the ICU in Podgorica. A larger sample of ICU patients would in-crease statistical power and allow for inclusion of more potential risk factors in the regression analysis.
C O N C L U S I O N
In conclusion, our study showed that ICU patients with a high number of prescribed drugs who receive antiarrhythmics, anticoagulants or double antiplatelet therapy are at higher risk of experiencing DDIs. Routine screening of such patients for potential DDIs by means of drug-drug interaction checking software may prevent a number of DDIs with potentially deleterious effects and increase their chances for survival and recovery.
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